What is Lumenis?
Founded in 1966 and based in Hesse, Germany, Lumenis Ltd. specializes in the development and commercialization of advanced energy-based technologies. Their product portfolio caters to skin, body, and eye care treatments, featuring notable solutions such as Trilift, OptiLight, Stellar M22, Optiplus, and Digital Duet. The company's long-standing presence in the market highlights its expertise and commitment to providing cutting-edge medical and aesthetic devices.
How much funding has Lumenis raised?
Lumenis has raised a total of $195M across 2 funding rounds:
Private Equity
$120M
Stock Offering
$75M
Private Equity (2006): $120M with participation from XT Group
Stock Issuance/Offering (2014): $75M, investors not publicly disclosed
Key Investors in Lumenis
XT Group
XT Group is a global holding company with diverse interests, including shipping and high-tech ventures. Their involvement suggests a strategic alignment with Lumenis's technological advancements and market potential.
What's next for Lumenis?
With a history of major enterprise-level funding and a recent strategic investment, Lumenis is poised for significant advancements. The substantial capital infusion, indicated by $195M and the recent $75M, suggests a strategic focus on scaling operations, enhancing research and development for next-generation technologies, and potentially expanding its global market reach. This backing will likely fuel innovation in energy-based treatments for dermatology, ophthalmology, and aesthetic procedures, reinforcing Lumenis's position as a leader in the field.
See full Lumenis company page
